Janice Gabrilove

Janice Gabrilove

Auto-generated profile, based on publicly available information

Janice Gabrilove

Icahn School of Medicine at Mount Sinai, New York, NY, USA

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2001 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
JGJanice L. Gabrilove
Janice L. Gabrilove
CCCharles S. Cleeland
Charles S. Cleeland
RLRobert B. Livingston
Robert B. Livingston
BSBrenda Sarokhan
Brenda Sarokhan
EWEric Winer
Eric Winer
LELawrence H. Einhorn
Lawrence H. Einhorn
PURPOSE: To prospectively evaluate the effectiveness, safety, and clinical benefits of once-weekly epoetin alfa therapy as an adjunct to chemotherapy in anemic cancer patients. PATIENTS AND METHODS: A total of 3,012 patients with nonmyeloid malignancies who received chemotherapy were enrolled onto this multicenter, open-label, nonrandomized study conducted in 600 United States community-based practices. Patients received epoetin alfa 40,000 U once weekly, which could be increased to 60,000 U once weekly after 4 weeks dependent on hemoglobin response. Treatment was continued for a maximum of 16 weeks. RESULTS: Among the 2,964 patients assessable for efficacy, epoetin alfa therapy resulted in significant increases in hemoglobin levels, decreases in transfusion requirements, and improvements in functional status and fatigue as assessed by the linear analog scale assessment (energy level, ability to perform daily activities, and overall quality of life) and the anemia subscale of the Functional Assessment of Cancer Therapy–Anemia questionnaire. Improvements in quality-of-life parameters correlated significantly (P < .001) with increased hemoglobin levels. The direct relationship between hemoglobin and quality-of-life improvement was sustained during the 16-week study period, which is similar to findings of large community-based trials of three-times-weekly dosing. Once-weekly epoetin alfa was well tolerated, with most adverse events attributed to the underlying disease or concomitant chemotherapy. CONCLUSION: The results from this large, prospective, community-based trial suggest that once-weekly epoetin alfa therapy increases hemoglobin levels, decreases transfusion requirements, and improves quality of life in patients with cancer and anemia who undergo concomitant chemotherapy. Based on the results of this study, the clinical benefits and the adverse event profile of once-weekly epoetin alfa therapy in community-based practice are similar to those observed in the historical experience with the three-times-weekly dosage schedule.

16 October 2023 in Journal of Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
TBTara G. Bautista
Tara G. Bautista
GRGretchen Roman
Gretchen Roman
MKMunziba Khan
Munziba Khan
MLMichele Lee
Michele Lee
SSSumeyra Sahbaz
Sumeyra Sahbaz
MBMiriam Bredella
Miriam Bredella
Well-being is a multifaceted construct that is used across disciplines to portray a state of wellness, health, and happiness. While aspects of well-being seem universal, how it is depicted in the literature has substantial variation. The aim of this scoping review was to identify conceptual and operational definitions of well-being within the field of occupational health. Broad search terms were used related to well-being and scale/assessment. Inclusion criteria were (1) peer-reviewed articles, (2) published in English, (3) included a measure of well-being in the methods and results section of the article, and (4) empirical paper. The searches resulted in 4394 articles, 3733 articles were excluded by reading the abstract, 661 articles received a full review, and 273 articles were excluded after a full review, leaving 388 articles that met our inclusion criteria and were used to extract well-being assessment information. Many studies did not define well-being or link their conceptual definition to the operational assessment tool being used. There were 158 assessments of well-being represented across studies. Results highlight the lack of a consistent definitions of well-being and standardized measurements.

20 May 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
STSantiago Thibaud
Santiago Thibaud
DTDouglas Tremblay
Douglas Tremblay
SBSheena Bhalla
Sheena Bhalla
BZBrittney Zimmerman
Brittney Zimmerman
KSKeith Sigel
Keith Sigel
JGJanice Gabrilove
Janice Gabrilove
Severe cases of coronavirus disease 2019 (COVID‐19) are usually accompanied by an exuberant immune response comparable to cytokine release syndrome (CRS), with markedly elevated serum levels of proinflammatory cytokines which are thought to be a major drivers of morbidity and mortality for these patients (Huang, et al 2020). Several drugs with anti‐inflammatory properties (tocilizumab, siltuximab, sarilumab, anakinra, among others) have been suggested as adjuncts to supportive care in the management of COVID‐19, and several clinical trials are underway (NCT04315298, NCT04317092, NCT04306705).

8 July 2008 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
JGJanice Gabrilove
Janice Gabrilove
RPRonald Paquette
Ronald Paquette
RLRoger M. Lyons
Roger M. Lyons
CMChaudhry Mushtaq
Chaudhry Mushtaq
MSMikkael A. Sekeres
Mikkael A. Sekeres
LDLyndah Dreiling
Lyndah Dreiling
Patients with myelodysplastic syndromes (MDS) often develop anaemia resulting in frequent transfusions and fatigue. Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anaemia. This single-arm, phase 2 study examined the efficacy of darbepoetin alfa 500 mu g every 3 weeks (Q3W) for treating anaemia in low-risk MDS patients (after 6 weeks, poor responders received darbepoetin alfa 500 mu g every 2 weeks). The primary end-point was the incidence of erythroid responses (International Working Group criteria) after 13 weeks of therapy. Secondary end-points included the incidence of erythroid responses at weeks 28 and 55, [or weeks 27 and 53 for dose escalations to every two weeks (Q2W)], and safety parameters. Analyses were stratified by the patient's previous ESA therapy status [ESA-naive (n = 144) vs. prior ESA-treated (n = 62)]. After 13 weeks of therapy, 49% of ESA-naive patients and 26% of prior ESA-treated patients achieved a major erythroid response. After 53/55 weeks, 59% of ESA-naive patients and 34% of prior ESA-treated patients achieved a major erythroid response; 82% of ESA-naive patients and 55% of prior ESA-treated patients achieved target haemoglobin of 110 g/l. Thromboembolic or related adverse events occurred in 2% of patients; no pulmonary embolisms were reported. In conclusion, darbepoetin alfa, 500 mu g Q3W appeared well tolerated and increased haemoglobin levels in low-risk MDS patients.

22 September 2021 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
HLHannah Levavi
Hannah Levavi
Guido Sebastian LancmanGuido Sebastian Lancman
Guido Sebastian Lancman
JGJanice Gabrilove
Janice Gabrilove

5 June 2020 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
CHCamille Hardy-Abeloos
Camille Hardy-Abeloos
RPRachel Pinotti
Rachel Pinotti
JGJanice Gabrilove
Janice Gabrilove
Background: Ibrutinib is a Bruton tyrosine kinase inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) in 2014. Ibrutinib is often used to treat patients who are younger than the patients originally included in theclinical trials have additional unfavorable prognostic factors and suffer from additional comorbidities excluded from the original phase III trials. Our objective was to examine current clinical practices and their impact in this expanded population of CLL patients who often require adjustments in the standard prescribed dose and schedule of therapy. Materials and methods: An extensive review of the medical literature was conducted to establish the consensus on ibrutinib dose modifications in patients with CLL. Twenty-nine studies were reviewed including fourteen clinical trials and fifteen “real-world practice” studies. Results: The average discontinuation rate was similar between clinical trials and “real-world practice” studies though the reasons for discontinuation differed. CLL progression was a more common reason for discontinuation in clinical trial studies while toxicity was a more common reason for discontinuation in “real-world practice” studies. Some studies have suggested worse outcomes in patients requiring dose reductions in ibrutinib while others have shown no change in treatment efficacy in patients requiring dose reductions due to concomitant CYP medications or increased immunosuppression post-transplant. Conclusion: The impact of ibrutinib dose modifications on clinical outcome remains unclear. Patients on concomitant CYP3A inhibitors should be prescribed a lower dose than the standard 420 mg daily, in order to maintain comparable pharmacologic properties. Further research is required to establish definitive clinical practice guidelines.